2024-04-11 16:35:02来源:中华医学会器官移植学分会阅读:437次
《中国肾脏移植临床诊疗指南》之47
肾脏移植受者尿路感染临床诊疗指南
中华医学会器官移植学分会
一、指南形成方法
表1 证据质量与推荐强度分级
二、肾脏移植术后尿路感染的流行病学和临床分类
三、肾脏移植术后尿路感染的诊断和治疗
五、小结:
执笔作者:管瑀(首都医科大学附属北京友谊医院),林俊(首都医科大学附属北京友谊医院),付绍杰(南方医科大学南方医院),周洪澜(吉林大学白求恩第一医院),王钢(吉林大学白求恩第一医院)
通信作者:
林俊(首都医科大学附属北京友谊医院)
Email:bfh-linjun@hotmail.com
薛武军(西安交通大学第一附属医院)
Email:xuwujun126@xjt.edu.cn
参编作者:丁光璞(首都医科大学附属北京友谊医院),张健(首都医科大学附属北京友谊医院),连鑫(吉林大学白求恩第一医院),周敏捷(南方医科大学南方医院),王志鹏(首都医科大学附属北京友谊医院),杨洋(首都医科大学附属北京友谊医院)
主审专家:薛武军(西安交通大学第一附属医院),门同义(内蒙古医科大学附属医院),陈刚(华中科技大学同济医学院附属同济医院),朱友华(海军军医大学长海医院),田野(首都医科大学附属北京友谊医院)
审稿专家(按姓氏笔画排序):丁小明(西安交通大学第一附属医院),王长安(郑州市第七人民医院),王祥慧(上海交通大学医学院附属瑞金医院),王强(北京大学人民医院),丰贵文(郑州大学第一附属医院),张雷(海军军医大学长海医院),孙启全(广东省人民医院),陈劲松(东部战区总医院),戎瑞明(复旦大学附属中山医院),朱一辰(首都医科大学附属北京友谊医院),李新长(江西省人民医院),吴建永(浙江大学医学院附属第一医院),宋文利(天津市第一中心医院),苗芸(南方医科大学南方医院),金海龙(解放军总医院第八医学中心),林涛(四川大学华西医院),周华(山西省第二人民医院),黄刚(中山大学附属第一医院),董震(青岛大学附属医院)
利益冲突:所有作者声明无利益冲突
参考文献
[1] HOLLYER I, ISON M G. The challenge of urinary tract infections in renal transplant recipients . Transpl Infect Dis, 2018, 20(2): e12828.
[2] ALANGADEN G J, THYAGARAJAN R, GRUBER S A, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors . Clin Transplant, 2006, 20(4): 401-9.
[3] ALANGADEN G. Urinary tract infections in renal transplant recipients . Curr Infect Dis Rep, 2007, 9(6): 475-9.
[4] MEENA P, BHARGAVA V, RANA D S, et al. Urinary tract infection in renal transplant recipient: A clinical comprehensive review . Saudi J Kidney Dis Transpl, 2021, 32(2): 307-17.
[5] LIM J H, CHO J H, LEE J H, et al. Risk factors for recurrent urinary tract infection in kidney transplant recipients . Transplant Proc, 2013, 45(4): 1584-9.
[6] CHUANG P, PARIKH C R, LANGONE A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers . Clin Transplant, 2005, 19(2): 230-5.
[7] ARIZA-HEREDIA E J, BEAM E N, LESNICK T G, et al. Urinary tract infections in kidney transplant recipients: role of gender, urologic abnormalities, and antimicrobial prophylaxis . Ann Transplant, 2013, 18: 195-204.
[8] HOSSEINPOUR M, PEZESHGI A, MAHDIABADI M Z, et al. Prevalence and risk factors of urinary tract infection in kidney recipients: a meta-analysis study . BMC Nephrol, 2023, 24(1): 284.
[9] MUNOZ P. Management of urinary tract infections and lymphocele in renal transplant recipients . Clin Infect Dis, 2001, 33 Suppl 1: S53-7.
[10] HOOTON T M, BRADLEY S F, CARDENAS D D, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America . Clin Infect Dis, 2010, 50(5): 625-63.
[11] VIDAL E, CERVERA C, CORDERO E, et al. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI) . Enferm Infecc Microbiol Clin, 2015, 33(10): 679 e1- e21.
[12] RUBIN R H, SHAPIRO E D, ANDRIOLE V T, et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration . Clin Infect Dis, 1992, 15 Suppl 1: S216-27.
[13] SAFDAR N, SLATTERY W R, KNASINSKI V, et al. Predictors and outcomes of candiduria in renal transplant recipients . Clin Infect Dis, 2005, 40(10): 1413-21.
[14] GERBER L, GASPERT A, BRAGHETTI A, et al. Ureaplasma and Mycoplasma in kidney allograft recipients-A case series and review of the literature . Transpl Infect Dis, 2018, 20(5): e12937.
[15] SILVA M, JR., MARRA A R, PEREIRA C A, et al. Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome . Transplantation, 2010, 90(5): 581-7.
[16] LINARES L, CERVERA C, COFAN F, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation . Transplant Proc, 2007, 39(7): 2222-4.
[17] PINHEIRO H S, MITUIASSU A M, CARMINATTI M, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients . Transplant Proc, 2010, 42(2): 486-7.
[18] BODRO M, SANCLEMENTE G, LIPPERHEIDE I, et al. Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients . Am J Transplant, 2015, 15(4): 1021-7.
[19] WEINER L M, WEBB A K, LIMBAGO B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014 . Infect Control Hosp Epidemiol, 2016, 37(11): 1288-301.
[20] VEROUX M, GIUFFRIDA G, CORONA D, et al. Infective complications in renal allograft recipients: epidemiology and outcome . Transplant Proc, 2008, 40(6): 1873-6.
[21] BRENNAN D C, DALLER J A, LAKE K D, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation . N Engl J Med, 2006, 355(19): 1967-77.
[22] FAYEK S A, KEENAN J, HARIRIAN A, et al. Ureteral stents are associated with reduced risk of ureteral complications after kidney transplantation: a large single center experience . Transplantation, 2012, 93(3): 304-8.
[23] THOMPSON E R, HOSGOOD S A, NICHOLSON M L, et al. Early versus late ureteric stent removal after kidney transplantation . Cochrane Database Syst Rev, 2018, 1(1): CD011455.
[24] ELIACIK K, KANIK A, YAVASCAN O, et al. A Comparison of Bladder Catheterization and Suprapubic Aspiration Methods for Urine Sample Collection From Infants With a Suspected Urinary Tract Infection . Clin Pediatr (Phila), 2016, 55(9): 819-24.
[25] LAROCCO M T, FRANEK J, LEIBACH E K, et al. Effectiveness of Preanalytic Practices on Contamination and Diagnostic Accuracy of Urine Cultures: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis . Clin Microbiol Rev, 2016, 29(1): 105-47.
[26] DUAN W, YANG Y, ZHAO J, et al. Application of metagenomic next-generation sequencing in the diagnosis and treatment of recurrent urinary tract infection in kidney transplant recipients . Front Public Health, 2022, 10: 901549.
[27] JIA K, HUANG S, SHEN C, et al. Enhancing urinary tract infection diagnosis for negative culture patients with metagenomic next-generation sequencing (mNGS) . Front Cell Infect Microbiol, 2023, 13: 1119020.
[28] MORAND A, CORNU F, DUFOUR J C, et al. Human Bacterial Repertoire of the Urinary Tract: a Potential Paradigm Shift . J Clin Microbiol, 2019, 57(3).
[29] SATHIANANTHAMOORTHY S, MALONE-LEE J, GILL K, et al. Reassessment of Routine Midstream Culture in Diagnosis of Urinary Tract Infection . J Clin Microbiol, 2019, 57(3).
[30] GREEN H, RAHAMIMOV R, GOLDBERG E, et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study . Eur J Clin Microbiol Infect Dis, 2013, 32(1): 127-31.
[31] FIORANTE S, LOPEZ-MEDRANO F, LIZASOAIN M, et al. Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients . Kidney Int, 2010, 78(8): 774-81.
[32] ARENCIBIA N, AGUERA M L, RODELO C, et al. Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients . Transplant Proc, 2016, 48(9): 2941-3.
[33] WAGENLEHNER F M, NABER K G. Editorial commentary: asymptomatic bacteriuria--shift of paradigm . Clin Infect Dis, 2012, 55(6): 778-80.
[34] LEE J R, BANG H, DADHANIA D, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients . Transplantation, 2013, 96(8): 732-8.
[35] MORADI M, ABBASI M, MORADI A, et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients . Urol J, 2005, 2(1): 32-5.
[36] RAO Z, WANG Z, TANG M, et al. Treatment of Asymptomatic Bacteriuria after Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials . Medicina (Kaunas), 2023, 59(9).
[37] BY THE AMERICAN GERIATRICS SOCIETY BEERS CRITERIA UPDATE EXPERT P. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults . J Am Geriatr Soc, 2015, 63(11): 2227-46.
[38] AL MOHAJER M, MUSHER D M, MINARD C G, et al. Clinical significance of Staphylococcus aureus bacteriuria at a tertiary care hospital . Scand J Infect Dis, 2013, 45(9): 688-95.
[39] MITRA S, ALANGADEN G J. Recurrent urinary tract infections in kidney transplant recipients . Curr Infect Dis Rep, 2011, 13(6): 579-87.
[40] VAN DUIN D, LOK J J, EARLEY M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae . Clin Infect Dis, 2018, 66(2): 163-71.
[41] RAZ R, STAMM W E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections . N Engl J Med, 1993, 329(11): 753-6.
[42] BEEREPOOT M A, TER RIET G, NYS S, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women . Arch Intern Med, 2012, 172(9): 704-12.
[43] LEE B S, BHUTA T, SIMPSON J M, et al. Methenamine hippurate for preventing urinary tract infections . Cochrane Database Syst Rev, 2012, 10(10): CD003265.
[44] JORGENSON M R, DESCOUROUEZ J L, SIODLAK M, et al. Efficacy and Safety of Probiotics and Synbiotics in Liver Transplantation . Pharmacotherapy, 2018, 38(7): 758-68.
[45] GRIN P M, KOWALEWSKA P M, ALHAZZAN W, et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis . Can J Urol, 2013, 20(1): 6607-14.
[46] STAPLETON A E, AU-YEUNG M, HOOTON T M, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection . Clin Infect Dis, 2011, 52(10): 1212-7.
[47] HOLLYER I, VARIAS F, HO B, et al. Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: A single center, retrospective study . Transpl Infect Dis, 2019, 21(3): e13063.
[48] JEPSON R G, WILLIAMS G, CRAIG J C. Cranberries for preventing urinary tract infections . Cochrane Database Syst Rev, 2012, 10(10): CD001321.
[49] HAIDAR G, PHILIPS N J, SHIELDS R K, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance . Clin Infect Dis, 2017, 65(1): 110-20.
[50] SHIELDS R K, POTOSKI B A, HAIDAR G, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections . Clin Infect Dis, 2016, 63(12): 1615-8.
[51] SUN D, RUBIO-APARICIO D, NELSON K, et al. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae . Antimicrob Agents Chemother, 2017, 61(12).
[52] TEN DOESSCHATE T, VAN WERKHOVEN H, MEIJVIS S, et al. Fosfomycin-trometamol for Urinary Tract Infections in Kidney Transplant Recipients . Transplantation, 2019, 103(6): 1272-6.
[53] CERVERA C, VAN DELDEN C, GAVALDA J, et al. Multidrug-resistant bacteria in solid organ transplant recipients . Clin Microbiol Infect, 2014, 20 Suppl 7: 49-73.
[54] ALVAREZ-LERMA F, NOLLA-SALAS J, LEON C, et al. Candiduria in critically ill patients admitted to intensive care medical units . Intensive Care Med, 2003, 29(7): 1069-76.
[55] RICHARDS M J, EDWARDS J R, CULVER D H, et al. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System . Pediatrics, 1999, 103(4): e39.
[56] HE Z, HUO X, LEI D, et al. Management of candiduria in hospitalized patients: a single-center study on the implementation of IDSA guidelines and factors affecting clinical decisions . Eur J Clin Microbiol Infect Dis, 2021, 40(1): 59-65.
[57] FISCHER S A, LU K, PRACTICE A S T I D C O. Screening of donor and recipient in solid organ transplantation . Am J Transplant, 2013, 13 Suppl 4(Suppl 4): 9-21.
[58] ISON M G, GROSSI P, PRACTICE A S T I D C O. Donor-derived infections in solid organ transplantation . Am J Transplant, 2013, 13 Suppl 4: 22-30.
[59] BRATZLER D W, DELLINGER E P, OLSEN K M, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery . Am J Health Syst Pharm, 2013, 70(3): 195-283.
[60] CENTERS FOR DISEASE C, PREVENTION. Transmission of multidrug-resistant Escherichia coli through kidney transplantation --- California and Texas, 2009 . MMWR Morb Mortal Wkly Rep, 2010, 59(50): 1642-6.
[61] MULARONI A, BERTANI A, VIZZINI G, et al. Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria . Am J Transplant, 2015, 15(10): 2674-82.
[62] LEN O, GARZONI C, LUMBRERAS C, et al. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections . Clin Microbiol Infect, 2014, 20 Suppl 7: 10-8.
[63] SIFRI C D, ISON M G. Highly resistant bacteria and donor-derived infections: treading in uncharted territory . Transpl Infect Dis, 2012, 14(3): 223-8.
[64] BISHARA J, GOLDBERG E, LEV S, et al. The utilization of solid organs for transplantation in the setting of infection with multidrug-resistant organisms: an expert opinion . Clin Transplant, 2012, 26(6): 811-5.
[65] BERTRAND D, PALLET N, SARTORIUS A, et al. Clinical and microbial impact of screening kidney allograft preservative solution for bacterial contamination with high-sensitivity methods . Transpl Int, 2013, 26(8): 795-9.
[66] LIANG H, ZHANG P, YU B, et al. Machine perfusion combined with antibiotics prevents donor-derived infections caused by multidrug-resistant bacteria . Am J Transplant, 2022, 22(7): 1791-803.
[67] MARTIN S I, FISHMAN J A, PRACTICE A S T I D C O. Pneumocystis pneumonia in solid organ transplantation . Am J Transplant, 2013, 13 Suppl 4: 272-9.
[68] FOX B C, SOLLINGER H W, BELZER F O, et al. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis . Am J Med, 1990, 89(3): 255-74.
[69] HIBBERD P L, TOLKOFF-RUBIN N E, DORAN M, et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial . Online J Curr Clin Trials, 1992, Doc No 15: [4083 words; 46 paragraphs].
[70] RAFAT C, VIMONT S, ANCEL P Y, et al. Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients . Transpl Infect Dis, 2011, 13(4): 344-52.
[71] WOJCIECHOWSKI D, CHANDRAN S. Effect of ciprofloxacin combined with sulfamethoxazole-trimethoprim prophylaxis on the incidence of urinary tract infections after kidney transplantation . Transplantation, 2013, 96(4): 400-5.
[72] KHORVASH F, MORTAZAVI M, HAKAMIFARD A, et al. Comparison of the effect of co-trimoxazole and co-trimoxazole plus ciprofloxacin in urinary tract infection prophylaxis in kidney transplant patients . Adv Biomed Res, 2016, 5: 108.
[73] MANGUS R S, HAAG B W. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis . Am J Transplant, 2004, 4(11): 1889-96.
[74] WILSON C H, RIX D A, MANAS D M. Routine intraoperative ureteric stenting for kidney transplant recipients . Cochrane Database Syst Rev, 2013, (6): CD004925.